Clinical Cancer Research · 2015 · 30 citations · 39 references
MedicineNuclear MedicineOncologyOncologic Nuclear MedicineRadiation DosimetryTherapeutic Nuclear MedicineAbsorbed DoseDose PrescriptionRadiation TherapyRadiation Treatment PlanningRadiobiological ConsiderationsDose-volume RelationshipRadiation BoostRadiation Dose ManagementTherapeutic DosimetryTumor DosimetryTumor Response EvaluationTumor Volume EstimationTumor Volume Measurement
PURPOSE: We tested therapeutic efficacy of two dose painting strategies of applying higher radiation dose to tumor subvolumes with high FDG uptake (biologic target volume, BTV): dose escalation and dose redistribution. We also investigated whether tumor response was determined by the highest dose in BTV or the lowest dose in gross tumor volume (GTV). EXPERIMENTAL DESIGN: FDG uptake was evaluated in rat rhabdomyosarcomas prior to irradiation. BTV was defined as 30% of GTV with the highest (BTVhot) or lowest (BTVcold) uptake. To test efficacy of dose escalation, tumor response (time to reach two times starting tumor volume, TGTV2) to Hot Boost irradiation (40% higher dose to BTVhot) was compared with Cold Boost (40% higher dose to BTVcold), while mean dose to GTV remained 12 Gy. To test efficacy of dose redistribution, TGTV2 after Hot Boost was compared with uniform irradiation with the same mean dose (8 or 12 Gy). RESULTS: TGTV2 after 12 Gy delivered heterogeneously (Hot and Cold Boost) or uniformly were not significantly different: 20.2, 19.5, and 20.6 days, respectively. Dose redistribution (Hot Boost) with 8 Gy resulted in faster tumor regrowth as compared with uniform irradiation (13.3 vs. 17.1 days; P = 0.026). Further increase in dose gradient to 60% led to a more pronounced decrease in TGTV2 (10.9 days; P < 0.0001). CONCLUSIONS: Dose escalation effect was independent of FDG uptake in target tumor volume, while dose redistribution was detrimental in this tumor model for dose levels applied here. Our data are consistent with the hypothesis that tumor response depends on the minimum intratumoral dose.
39
Hypoxia and Glucose Metabolism in Malignant Tumors
Joseph G. Rajendran, David A. Mankoff, Finbarr O’Sullivan et al. · Clinical Cancer Research · 2004 · 391 citations · Full text
Medicine, Nuclear Medicine, Oncology +17
Farrokh Dehdashti, Perry W. Grigsby, Jason S. Lewis et al. · Journal of Nuclear Medicine · 2008 · 213 citations · Full text
Dependence of FDG uptake on tumor microenvironment
Andrei Pugachev, Shutian Ruan, Sean Carlin et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 194 citations
Medicine, Cancer Biology, Oncology +12